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1. Introduction 
Amyotrophic Lateral Sclerosis (ALS) is the most common adult-onset neurodegenerative 
disorder characterized by the death of large motor neurons in the cerebral cortex and spinal 
cord (Tandan and Bradley, 1985). Dysfunction and death of these cell populations lead to 
progressive muscle weakness, atrophy, fasciculations, spasticity and ultimately, paralysis 
and death usually within 3 to 5 years after disease onset (Mulder, 1982). The estimated 
worldwide incidence for this disease is around 2 per 100,000 in the general population and 
the life-long risk to develop ALS is approximately 1:2000. The disease occurs in sporadic 
(90%) and familial forms (10%) (Gros-Louis, et al., 2006). With the exception of few FALS 
cases in which other neurodegenerative disorders can simultaneously occur, FALS and 
SALS are clinically indistinguishable. To date, mutations in the Cu/Zn superoxide 
dismutase 1 (SOD1) gene have remained the major known genetic causes associated with 
ALS. However, the mechanism whereby mutant SOD1 causes specific degeneration of 
motor neurons remains unclear. Nonetheless, many neuronal death pathways have been 
revealed through studies with transgenic mice expressing SOD1 mutants. Other vertebrate, 
invertebrate and in vitro models of ALS have also been described. Here, we will review 
various animal and cellular models that have been used to study the toxicity of ALS-linked 
gene mutations and also to investigate pathological hallmarks of the disease.  
1.1 Familial ALS 
Though most cases of ALS are sporadic, 10% of cases have affected relatives, some with 
clear Mendelian inheritance and high penetrance (Gros-Louis, et al., 2006). The landmark 
discovery in 1993 of missense mutations in the SOD1 gene in subsets of familial cases 
directed most ALS research to elucidate the mechanism of SOD1-mediadted disease (Rosen, 
et al., 1993). More recently, mutations in two other genes, TARDBP and FUS/TLS have been 
found in ALS patients (Kabashi, et al., 2008; Sreedharan, et al., 2008; Vance, et al., 2009). Rare 
mutations in other genes such as ANG, ALS2, DCTN1, MAPT, SETX and VAPB have also 
been described (for reviews see (Gros-Louis, et al., 2006)). Various other genetic mutations in 
the ELP3 ((Simpson, et al., 2009), FIG4 (Chow, et al., 2009), DAO (Mitchell, et al., 2010), 
OPTN (Maruyama, et al., 2010) and CHGB (Gros-Louis, et al., 2009a) genes have also been 
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associated with the disease through several candidate gene-based association studies. Given 
the high degree of genetic and clinical heterogeneity seen in ALS patients, along with 
population-specific genetic risk factors for ALS, independent replication of these genetic 
association studies would be crucial in order to better understand the different mechanisms 
involved in these disease. As there are several excellent reviews in the literature describing 
these genes and their relevance to ALS, we will mainly describe the most recent and exciting 
advances involving SOD1, TARDBP and FUS in this area. 
To date, family-based linkage studies and positional cloning have led to the identification of 
fifteen ALS-associated genes in which mutations have been identified in familial ALS cases 
(Table 1). Different research groups or consortiums have replicated these results in several 
populations. To date, a number of genes have been discovered as causative for the classical 
adult onset form of familial ALS with typical symptoms, namely SOD1, TARDBP, FUS/TLS, 
and C9ORF72 (DeJesus-Hernandez, et al., 2011; Kabashi, et al., 2008; Kwiatkowski, et al., 
2009; Renton, et al., 2011; Rosen, et al., 1993; Sreedharan, et al., 2008). These genes 
cumulatively account for about 25% of familial cases, indicating that other causative genes 
remain to be identified. The difficulties to identify gene responsible for FALS arise in part 
because large families with sufficient statistical power for linkage analysis are hard to come 
by, due to the late-onset and age-dependant penetrance of the disease, and the relative short 
survival time of affected ALS patients. Furthermore, the high degree of genetic 
heterogeneity, i.e. many rare variants in many different genes individually having a modest 
effect on the total number of ALS cases, is also certainly a limiting factor for the 
identification of causative ALS-predisposing genes. Four other genes, namely DAO, OPTN, 
ATAX2 and VCP have also been included in this category, but the evidence for their role in 
predisposing to classical ALS needs to be confirmed in replication studies, and more 
families linked to these genes also need to be described (Elden, et al., 2010; Johnson, et al., 
2010; Maruyama, et al., 2010; Mitchell, et al., 2010).  
 
FALS-associated known genes (gene symbol) Inheritance Onset Mutation types References
Superoxyde dismutase 1 (SOD1) AD Adult Missense and truncation mutation Rosen et al., 1993
TAR DNA-binding protein (TARDBP) AD Adult Missense and nonsense mutations Kabashi et al., 2008; Sreedharan et al., 2008
Fused in sarcoma/translated in liposarcoma (FUS/TLAD and AR Adult Missense mutations, indels Kwiatkowski et al., 2009; Vance et al., 2009
Chromosome 9 opend reading frame 72 (C9ORF72) AD Adult Hexanucleotide GGGGCC expansion repeaenton et al., 2011, DeJesus-Hernandez et al., 201
Ataxin 2 (ATAX2) AD Adult Trinucleotide CAG expansion repeat Elden et al., 2010
Ubiquitin-like protein ubiquilin2 (UBQLN2) X-linked Adult Missense mutations Deng et al., 2011
Optineurin (OPTN) AD Adult Missense and nonsense mutations Maruyama et al., 2010
D-amino acid oxidase (DAO) AD Adult One R199W missense mutation Mitchell et al., 2010
Amyotrophic lateral sclerosis 2 (ALS2) AR Juvenile Missense and nonsense mutations Hadano et al., 2002, Yang et al., 2002
Valosin-containing protein (VCP) AD Adult Missense mutations Johnson et al., 2010
Vesicle-associated membrane protein B (VAPB) AD Adult Missense mutations Nishimura et al., 2004
Microtubule-associated protein tau (MAPT) AD Adult Missense and 5'-splice-site mutations Hutton et al., 1998
Dynactin 1 (DCTN1) AD Adult Missense mutations Puls et al., 2003
Angiogenin AD Adult Missense mutations Chen et al., 2004
Senataxin (SETX) AD Juvenile Missense mutations Greeway et al., 2006  
Table 1. Identified genes predisposing for familial ALS and/or ALS-FTLD 
FALS: Familial ALS, ALS-FTLD: ALS with frontotemporal lobar degeneration,  
AD: autosomal dominant, AR: autosomal recessive, Indels: insertions, deletions 
The identification of other genes responsible for the disease and the understanding of the 
molecular pathways involved will bring some new insights into the mechanisms of disease 
pathogenesis, and may also elucidate the underlying mechanism(s) for specific motor 
neuron degeneration observed in ALS.  
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1.2 Sporadic ALS 
For most cases of ALS, the causes are unknown. A genetic component is also thought to 
contribute to the pathogenesis of sporadic ALS, which accounts for the majority of ALS 
cases. However, identification of gene mutations associated with SALS has met with limited 
success so far. Several groups have reported on gene variants and association studies found 
in individuals with sporadic ALS, each accounting for a small number of the total cases 
reflecting a complex pattern of inheritance with very low penetrance, a high degree of 
heterogeneity and/or the existence of environmental factors predisposing to ALS. Because 
familial and sporadic forms of the disease are clinically and pathologically similar, 
understanding the familial form will shed light on possible epidemiological and 
pathophysiological mechanisms in SALS.  
Many divergent data generated by different research groups who have studied different 
populations around the world have been published. The use of an adequate size population 
with appropriate control individuals is needed in order to reach enough statistical power 
and to observe any significant results. Homogeneity regarding ethnical origin, age, age of 
onset, disease duration, site of the first symptoms and gender among the studied 
populations is essential to design a good and robust genetic study. The requirement for 
larger sample sizes and possibly more sensitive and efficient analytic tools allowing for 
reliable detection across studied populations are now becoming more and more available as 
non cost-effective genotyping strategies are being developed. 
The identifications of different genes and genetic risk factors associated with ALS over the past 
years have highlighted common molecular pathways mainly involving intracellular cell 
trafficking and RNA metabolism. To what extent these pathways are implicated in ALS 
remain to be determined and studied further. However, it is interesting to note that genes such 
as ALS2, VAPB, MAPT, DCTN1, EAAT2, NEFH, PRPH, FIG4, CNTF, CHGB and OPTN in 
which mutations have been found in a subset of FALS and/or SALS patients, are all related to 
intracellular trafficking either via axonal transport, vesicle docking and transport, or 
microtubule and neurofilament stabilization. Furthermore, this common theme is also seen in 
other motor neuron diseases and neurodegenerative disorders such as hereditary spastic 
paraplegia, Parkinson’s disease, spinal muscular atrophy and Charcot-Marie-tooth disease. It 
is also noteworthy that RNA metabolism via alternative splicing abnormalities or RNA 
binding is also a common theme observed amongst the different ALS related genes such as 
ALS2, MAPT, EAAT2, PRPH, GluR2, CNTF, SETX, SMN1, SMN2, TARDBP and FUS/TLS. The 
high degree of genetic heterogeneity observed in ALS suggests that an individual phenotype 
could result from the sum of several contributing gene defects and/or epigenetic influences, 
which individually do not cause disease, and may explain the difficulties in identifying genes 
associated with SALS. The identification of other genes associated with motor neuron disease, 
as well as the determination of genetic and/or environmental factors that predispose to SALS 
is crucial in the development of novel therapies for ALS. The generation of cellular or animal 
models to study SALS, in which the disease can be closely replicated, would also be the utmost 
importance to reach a full understanding of the molecular mechanisms and environmental 
factors associated with SALS. 
1.3 ALS with cognitive impairments 
In recent years, key developments have revealed a novel neurodegenerative disease 
spectrum with clinical symptoms overlapping between ALS and frontotemporal lobar 
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degeneration (FTLD) (Strong and Yang, 2011). Cognitive and behavioral impairment is well 
described in ALS with a significant proportion of patients meeting strict diagnostic criteria 
for FTLD. Neuroimaging and pathological studies have shown clear involvement of non-
motor areas of the brain. More recently, distinct subtypes of frontotemporal lobar 
dysfunction have been identified in ALS and further work to distinguish these phenotypes 
and their correlate neuropathology is under way. Attention has been devoted lately to a 
gene coding for a DNA/RNA binding protein, which have been implicated in the 
pathogenesis of ALS with cognitive impairments. Indeed, dominant mutations in the 
TARDBP gene, encoding for TDP-43, were reported by several groups as a primary cause of 
ALS in about 3% familial cases and 1.5% sporadic cases (Chio, et al., 2011; Corrado, et al., 
2009; Daoud, et al., 2009; Gitcho, et al., 2008; Kabashi, et al., 2008; Millecamps, et al., 2010; 
Sreedharan, et al., 2008; Van Deerlin, et al., 2008). The discovery of gene mutations linked to 
human ALS has provided plethora opportunities to develop model systems for 
investigating mechanisms of TDP-43 associated disease. 
Motor neuron degeneration can also occasionally occurs in patients with Parkinson’s disease 
and frontotemporal dementia (FTD). This disease is also called Disinhibition-dementia-
parkinsonism-amyotrophy complex (DDPAC) or FTDP17 (Lynch, et al., 1994). The pathologic 
features distinguish this disease from the ALS-parkinsonism-dementia complex of Guam seen 
in the peninsula of Japan and from ALS-FTD linked to chromosome 9. Mutations in the 
microtubule-associated protein tau gene (MAPT) have been shown to be associated with FTD and 
Parkinsonism (Hutton, et al., 1998). Tau is a member of the microtubule-associated protein 
family, which have the principal function stabilizing microtubules and promoting their 
assembly by binding to tubulin. As a number of reviews (Gros-Louis, et al., 2006; Julien and 
Kriz, 2006) have already described the relationship between MAPT and ALS, the following 
sections will not discuss in details about this gene and FTDP17 models that have been 
generated. 
2. In vivo models to study ALS 
The exact mechanisms by which all the above-described gene products are involved in 
ALS pathogenesis are the subject of many ongoing researches. Current thinking about 
ALS pathogenesis revolves around the interplay between pre-existing genetic 
susceptibility and environmental factors that may trigger disease. The search for putative 
environmental factors has remained elusive however; transgenic animal studies have 
yielded the greatest wealth of information to date. Through these studies, multiple 
cellular pathways have been identified including, protein misfolding, RNA processing, 
oxidative stress, excitotoxicity, axonal transport, mitochondrial dysfunction and 
abnormal secretion of proteins. Nevertheless, how accurately these animal models 
replicate all ALS clinical symptoms of the human illness remains an unanswered and 
troublesome question. This section will include the complete description of all published 
invertebrate and vertebrate models of ALS. Other considerations such as advantages, 
disadvantages, cost and availability of each model will also be discussed. Each model 
organism has its own advantages and disadvantages. Choosing an appropriate model 
depends on the question being asked. Many laboratories find it useful to perform 
parallel experiments in two or more model systems to understand different aspects of a 
biochemical process. 
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2.1 Invertebrate models 
Invertebrate model organisms include systems such as the simple yeast (fungi), fly, and 
nematode. The study of these experimental systems began with genetics and development, 
moved into molecular and cellular biology prior to most recently propelled into functional 
genomics and proteomics. These model organisms have highly manipulable genomes 
allowing for rapid generation of transgenic lines to provide insight on gene functions and 
protein network interactions. In 2002, Sydner Brenner, Robert Horvitz and John Sulston 
received the Nobel Prize in Physiology and Medicine for their establishment of the 
nematode Caenorhadditis elegans as a novel model organism to explore the molecular bases of 
organ development and cell death. Their discoveries identified key genes involved in cell 
division, differentiation and apoptosis. They determined that these genes were in fact highly 
conserved both structurally and functionally with higher organisms, including humans. 
Their studies provided the framework in which simpler organisms can be used to define key 
pathways and processes of relevance with the important benefit that the results are often 
directly applicable to understand human diseases.   
The key points into generating models for human disease using smaller invertebrate 
organisms should encompass high degree of conservation with mammals in order for the 
model to be useful for the identification of the molecular components implicated in disease 
pathogenesis. A fully sequenced genome of the studied organism should ideally be also 
easily accessible for genome comparison with higher vertebrates and mammals in order to 
facilitate evolutionary genomics studies and to quickly generate transgenic animals through 
DNA transformation. The model organism should also provide significant experimental 
advantages over their mammalian counterparts, including a short generation time, small 
size, ease and reasonable cost of maintenance.  It should be also amenable to both forward 
(phenotype to gene) and reverse (gene to phenotype) genetic approaches, which are 
essential molecular tools to dissect out and understand gene function. Classic forward 
genetic characteristics allow for the identification of novel molecules or pathways involved 
in a particular cellular process. This can be one of the most powerful attributes of 
invertebrate models. Forward-genetic screens using chemical mutagens are one of the most 
universal ways to generate mutants to elucidate gene function. On the other side, reverse 
genetics allows the quick identification of pathways on which a particular gene acts. Genetic 
knockdown mutants, using RNA interference (RNAi) technology in which a gene product is 
dramatically reduced by introducing double-stranded RNA (dsRNA) into the organism, can 
also provide invaluable information on the role a gene plays in a biological process. 
The obvious disadvantage of using invertebrate model organisms such as fly or worm 
models is that there are evolutionarily far from mammals and that many physiological 
functions are not conserved, e.g. the immune system.  Furthermore, their organs are 
extremely undeveloped and simple compared to other animals. The limited cellular 
diversity also represents a major disadvantage. 
2.1.1 Caenorhabditis elegans 
Yet, for the vast majority of neurodegenerative disorders including ALS, the mechanisms 
underlying neuronal dysfunction and death remain poorly understood despite the 
identification of relevant disease genes. Given the fact that molecular conservation in 
neuronal signaling pathways across vertebrate and invertebrate is relatively high and since 
the Caenorhabditis elegans nervous system contains almost all of the known signaling and 
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neurotransmitter systems found in mammals (Bargmann, 1998), many researchers have 
turned to this model organism to identify the mechanisms underlying neurodegenerative 
disease pathology.  
Research in C. elegans has been instrumental, especially over the last decade, for the 
elucidation of molecular pathways implicated in many human diseases. This is highly 
related to the fact that the C. elegans genome was the first multicellular organism to be 
completely sequenced in 1998 (Anonymous, 1998). The worm genome contains 
approximately 20,000 genes, compared with 25,000 in the human genome highlighting that 
C. elegans is a powerful model system for genetic analysis and for exploring the molecular 
mechanisms of neuron development, function, and disease. Furthermore, at least 42% of 
human disease related genes have a C. elegans ortholog, suggesting that most biochemical 
pathways are conserved across evolution (Culetto and Sattelle, 2000). 
 
 
Fig. 1. Transgenic UNC-47:GFP C. elegans 
In C. elegans, 26 neurons of 5 different classes express the neurotransmitter Gamma-
Aminobutyric Acid (GABA) (McIntire, et al., 1993). Nineteen of these GABAergic neurons, 
known as the type D neurons, are required for normal locomotion by providing 
dorsoventral cross-inhibition to body wall muscles (McIntire, et al., 1993; White, et al., 1986). 
Therefore, this transgenic worm would be a good model to depict pathological changes 
associated with locomotor dysfunction. Arrowheads point to type D neurons (only some of 
the D neurons are indicated). Courtesy of Dr Alex J. Parker from the Centre of Excellence in 
Neuromics, University of Montreal, Quebec, Canada. 
C. elegans is a free-living nematode of about 1 millimeter in length with a short generation 
cycle (3 days) and lifespan (around 3 weeks), large brood size (approximately 300 progeny 
from a single hermaphrodite), and a transparent anatomically simple body that allows for 
the visualization of all cell types at all stages of development (Brenner, 1974). This last 
feature allows researchers to easily detect and quantify neuronal cell death and protein 
inclusions using optical techniques. The complete C. elegans embryonic cell-lineage is also 
known, making it possible to follow organogenesis from the earliest stages of embryos 
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formation to the terminal steps of differentiation and morphogenesis (Sulston, et al., 1983). 
Additionally, C. elegans have a simple nervous system of 302 neurons out of 959 cells in the 
adult hermaphrodite, in which each neuron has a unique position (Sulston, 1983). Twenty of 
these neurons are located inside the pharynx, which has its own nervous system. The 
remaining 282 neurons are located in various ganglia in the head and tail and also along the 
ventral cord, the main longitudinal axon tract (Fig. 1). The majority of the neurons develop 
during embryogenesis. However, 80 of them, mainly motor neurons, develop post-
embryonically. The structure of the nervous system is highly reproducible from animal to 
animal and has been described in detail by electron microscopic reconstruction (White, et al., 
1986) This technique allowed White and colleague to obtain high-resolution images to 
identify all the synapses formed in C. elegans (about 5000 chemical synapses, 2000 
neuromuscular junctions and some 500 gap junctions) and to map all the connections in 
order to work out the entire neuronal circuit of this model organism. 
In addition, gene knockdown by RNA interference can be relatively easily achieved in most 
cell types in vivo or in vitro by injecting the double stranded RNA for a specific gene of 
interest, by simply soaking the animals in dsRNA, or by feeding the animals with bacteria 
expressing the desired dsRNA (Fire, et al., 1998; Maeda, et al., 2001). Primary neuronal and 
muscular cell cultures obtained by dissecting this animal have also been optimized to allow 
for stable growth of embryonic cells (Christensen, et al., 2002).  
For all these reasons, C. elegans has emerged as an attractive and powerful in vivo model 
system for studying pathological mechanisms in several major neurodegenerative disorders, 
including ALS, providing clear leads towards the identification of potential targets for the 
development of new therapeutic interventions against human diseases. 
2.1.1.1 C. Elegans SOD1 models 
A number of C. elegans models have been developed that recapitulate many aspects of ALS 
pathogenesis. These transgenic models mainly expressed either the SOD1 or the TDP-43 
protein under the control of various gene promoters. The first C. elegans ALS model was first 
generated in 2001 (Oeda, et al., 2001).  This transgenic C. elagans model has been generated 
by introducing human wild type and various human FALS SOD1-linked mutations (A4V, 
G37R and G93A) under the control of hsp16-2 heat shock and myo-3 muscle-specific 
promoters. The heat inducible hsp16-2 promoter allows expression of mutant SOD1 in 
almost all tissues, including neurons, while the myo-3 muscle-specific promoter allows high 
level of protein expression in all of the muscle tissues except for the pharynx. Unfortunately, 
no morphological abnormalities and no discernable changes in survival or behavior were 
observed. However, the authors reported some interesting findings.  The mutant SOD1 
expressing nematodes showed a reduced resistance to paraquat-induced oxidative stress. 
Furthermore, oxidative stress significantly reduced the degradation rate of mutant SOD1 
protein, and finally aberrant accumulation of mutant human SOD1 proteins was also 
observed when expressed in muscle cells.  Interestingly, this later pathological phenotype is 
in line with the pathology observed in human post-mortem ALS tissues.   
In a subsequent study, pan-neuronal expression of the G85R ALS-linked mutant form of 
human SOD1, using the C. elegans syntobrevin gene promoter (snb-1), coupled to a yellow 
fluorescent protein (YFP) produces strong locomotor defects and paralysis in this transgenic 
snb-1/G85RSOD1-YFP C. elegans model (Wang, et al., 2009a). Interestingly, the observed 
phenotype correlated with intra-neuronal SOD1 aggregation. Another SOD1 mutant C. 
elegans model in which aggregation, toxicity, and cellular interactions can be directly 
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compared between different SOD1 mutants was also reported. This mutant SOD1-YFP 
model, expressing various SOD1 mutants (G85R, G93A, 127X) in C. elegans muscle cells by 
the use of the muscle specific unc-54 gene promoter resulted in mild cellular dysfunction 
(Gidalevitz, et al., 2009). However, when mutant SOD1 was introduced into genetic 
backgrounds harboring destabilizing temperature-sensitive mutations, the toxicity was 
enhanced significantly and a variety of toxic phenotypes were observed. Based on theses 
results, the authors concluded that the specific toxic phenotypes may not be simply due to 
aggregation toxicity of the causative mutant proteins, but may be modulated by the genetic 
interactions with cellular pathways harboring mildly destabilizing polymorphisms in the 
genetic background. 
2.1.1.2 C. Elegans TDP-43 models 
In order to study TDP-43 function and neurotoxicity, transgenic C. elegans model was 
generated allowing pan-neuronal expression of the wild-type TDP-43 human protein (Ash, 
et al., 2010). This was done using the snb-1 gene promoter driving the expression of human 
TDP-43 cDNA in all neurons. The transgenic snb-1/hTDP-43 worms displayed a distinctive 
uncoordinated phenotype characterized by non-sinusoidal, slow movement and 
inappropriate responses to stimulus. Transgenic worms first display this phenotype during 
larval stages, and the phenotype remains constant throughout the adulthood. The authors 
have also found that this uncoordinated phenotype correlated with abnormal motor neuron 
synapses. The mechanism by which nuclear TDP-43 activity leads to abnormal synapses is 
still unknown, but the authors hypothesized that excessive TDP-43 activity may alters some 
component of RNA metabolism (e.g. alternative splicing), subsequently leading to altered 
production of specific proteins required for proper synaptic function. In another study, also 
describing a C. elegans model of TDP-43 proteinopathy, Liachko and colleagues similarly 
found that overexpression of normal human TDP-43 in all C. elegans neurons causes motor 
defects (Liachko, et al., 2010). However, they also found that overexpression of various 
human ALS-associated TDP-43 mutants (G290A, A315T, or M337V) cause a more severe 
motor dysfunction phenotype. Interestingly, the authors also demonstrated that the 
observed motor phenotype worsen over time and that the described mutant TDP-43 C. 
elegans model recapitulates some characteristic features seen in ALS and FTLD-U patients 
including progressive paralysis, reduced lifespan, and degeneration of motor neurons 
accompanied by hyperphosphorylation, truncation, and ubiquitination of the TDP-43 
protein that accumulates in detergent insoluble protein deposits. 
All the above described C. elegans models provide a good in vivo system to further dissect 
cellular and molecular mechanisms underlying disease. Further investigations using these 
models may reveal insights into SOD1 and TDP-43 functions, potentially reveal neurotoxic 
mechanisms relevant to ALS and other neurodegenerative diseases, and ultimately lead to 
the development of novel therapeutic targets. 
2.1.2 Drosophila melanogaster 
The fruit fly Drosophila melanogaster is a powerful genetic tool to study neurodegenerative 
diseases. Drosophila is a complex organism, with a functioning brain and nervous system, 
capable of many behaviors like learning, motility, and visual acuity. This model organism is 
one of the oldest multi cellular eukaryotic genetic models and has been used for almost a 
century to examine a variety of basic biological principles, including genetic inheritance, 
behavioral and developmental processes, and the first experimental description of the gene 
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as a functional unit. Its importance for human health was recognized by the award of the 
Nobel Prize in Physiology and Medicine to Ed Lewis, Christiane Nusslein-Volhard and Eric 
Wieschaus in 1995 for their discoveries concerning the genetic control of early embryonic 
development using D. melanogaster as a model. 
 
 
Fig. 2. Expression of human Ataxin3 gene in the compound eye of transgenic flies using the 
GAL4/UAS system. 
Transgenic drosophila expressing human full-length WT or mutated Ataxin 3 (ATXN3) gene 
in the compound eye. Only mutant ATAXN3 flies showed an external and internal 
degeneration, which is characterized by cell death and irregular ommatidia and 
photoreceptor distribution. Courtesy of Dr Guy A. Rouleau from the Centre of Excellence in 
Neuromics, University of Montreal, Quebec, Canada. 
Drosophila is cheap, of small size (approximately 2.5mm) and easy to maintain in the 
laboratory. One of the most attractive aspects of Drosophila for use as a model organism is its 
short reproductive cycle and large number of genetically identical progeny. Adult females 
can lay, following a circadian pattern, over 400 eggs within 10 days and their short 2-week 
generation time allows for quick analysis of mutant animals. The fly has only four pairs of 
chromosomes, including three autosomal chromosomes and one set of sexual X/Y 
chromosomes which can be directly visualized in the giant polytene chromosome of the 
larval salivary gland. The Drosophila genome has been completely sequenced (Adams, et al., 
2000). Its entire genome is encoded by roughly 13,600 genes as compared to 25,000 human 
genes. Another interesting feature of the fly is that it is relatively easy to drive time- and 
tissue-specific expression of any gene of interest using the yeast transcription activator 
protein Gal4 in combination with the Upstream Activation Sequence (UAS) to which Gal4 
specifically binds to activate gene transcription (Brand and Perrimon, 1993). To study 
neurodegenerative diseases, the compound eye is predominantly used because it allows the 
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generation of a neurodegenerative phenotype (rough eye phenotype) that can be easily 
appreciated under a standard light microscope (Fig. 2). In turn, the Gal4/UAS system can be 
also used to screen for genetic modifier (enhancer or suppressor) genes. 
Based on these observations, it is obvious that Drosophila melanogaster can offer unique 
opportunities in the study of human neurodegeneration.  Nonetheless, the major 
disadvantage of using D. melanogaster as a model is that forward genetic screen using RNA 
interference technology is more tedious than in the C.elegans model. For instance, at the 
moment, knockdown of genes by RNAi cannot be carried out by simply feeding flies with 
double-stranded RNA (as in the worm model); it has to be injected into the embryo. 
Although very laborious, this problem could be overcome by generating transgenic 
constructs expressing dsRNA for each transcript.  
2.1.2.1 Drosophila SOD1 models 
Initial ALS studies in Drosophila showed either reduced longevity and fertility, increased 
susceptibility to oxidative stress, motor deficits and/or necrotic cell death in the fly eye of 
Sod null flies (Phillips, et al., 1989).  Surprisingly, subsequent studies in transgenic fly model, 
overexpressing human WT SOD1 only in motor neurons, showed an extension of lifespan, 
without affecting locomotion or motor neuron survival (Parkes, et al., 1998). In contrast, 
another study showed that selective expression of WT or human SOD1 (hSOD1) disease-
linked (A4V, G85R) mutants in motor neurons induced progressive motor dysfunctions, 
coupled with electrophysiological defects and abnormal accumulation of the protein and a 
stress response in surrounding glial cells (Watson, et al., 2008). These effects were 
accompanied by synaptic transmission deficits, focal accumulation of hSOD1 in motor 
neurons, and up-regulation of heat shock protein in glia. This work suggests that SOD can 
cause cell-autonomous damage to motor neurons, and highlights that motor neuron 
selective expression of hSOD1 can induces change in glial cells. These results are in line with 
findings that disease is not strictly autonomous to motor neurons and that toxicity can 
propagate from one cell to another (Boillee, et al., 2006; Clement, et al., 2003). Expression of a 
human SOD1 transgene in Drosophila motor neurons was achieved by using the yeast 
GAL4/UAS system. Interestingly, Mocket and colleagues showed that human WT SOD1 
expression, placed in a Drosophila Cu-Zn Sod null background, at very low levels was 
sufficient to rescue the life-span reduction, increased oxidative stress, and impaired 
physiological function associated with the Drosophila Sod null model described above 
(Mockett, et al., 2003). However, the introduction of FALS-linked SOD1 alleles (A4V, G37R, 
G41D, G93C, and I113T) only partly reversed these effects. These results, in conjunction with 
earlier findings from FALS SOD1 expression restricted to motor neurons, suggest that the 
introduction of FALS mutant SOD1 alleles in Drosophila does not result in a dominant gain-
of-function, as it is observed in human patients.  
2.1.2.2 Drosophila TDP-43 models 
A number of models for TDP-43 toxicity in flies have also been generated, revealing that the 
protein shows toxicity in vivo. Mainly, these independent studies have examined 
phenotypes associated with manipulation of both endogenous Drosophila TDP-43 ortholog 
(dTDP) and transgenic expression of human TDP-43. The major findings of these 
complementary studies were largely consistent with one other. Flies lacking dTDP appeared 
externally normal but presented deficient locomotive behaviors, reduced life span, 
anatomical defects at the neuromuscular junctions and decreased dendritic branching 
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(Feiguin, et al., 2009; Lin, et al., 2011; Lu, et al., 2009). These phenotypes were rescued by 
expression of the human TDP-43 protein in a restricted group of neurons including motor 
neurons (Feiguin, et al., 2009). These findings support the notion that loss of normal TDP-43 
function may contribute to the pathogenesis of ALS and FTLD. On the other hand, 
ubiquitous or tissue-specific overexpression of either dTDP or human TDP-43 also 
recapitulated key hallmark features of ALS pathology including premature lethality, 
neuronal loss, neuromuscular junctions architecture defects and locomotor deficits (Elden, et 
al., 2010; Estes, et al., 2011; Hanson, et al., 2010; Li, et al., 2010; Lu, et al., 2009; Miguel, et al., 
2011; Ritson, et al., 2010; Voigt, et al., 2010). Furthermore, TDP-43 expression appears to be 
independent of ALS/FTLD-linked mutations (Elden, et al., 2010; Estes, et al., 2011; Ritson, et 
al., 2010; Voigt, et al., 2010). These results also support the view of a toxic dominant gain-of-
function mechanism(s) associated with TDP-43 proteinopathies. 
To further explore the role of TDP-43 pathogenesis and identify pathogenic mechanisms, 
several independent research groups have used different genetic approaches to identify 
modifier genes that could suppress or enhance TDP-43 toxicity (Elden, et al., 2010; Hanson, 
et al., 2010; Ritson, et al., 2010). Interestingly, upregulation of Pab1-binding protein 1 (Pbp1), 
an ortholog of the human ATXN2 gene, in a transgenic model of TDP-43 enhanced TDP-43 
toxicity and led to a more severe TDP-43 associated phenotypes (Elden, et al., 2010). 
Similarly, overexpression of ubiquilin 1, a previously identified TDP- 43 interacting partner 
(Kim, et al., 2009), reduced steady-state TDP-43 expression but enhanced the severity of 
TDP-43 phenotypes (Hanson, et al., 2010). Another study also showed that the TDP-43 
associated phenotypes observed in a transgenic Drosophila TDP-43 model was modulated by 
coexpression of valosin-containing protein (VCP), a member of the ATPases associated with 
multiple cellular activities (AAA+) family of proteins regulating a wide array of cellular 
processes (Ritson, et al., 2010). Further investigations on these interesting findings may 
enable the development of novel therapeutics targets that can regulate TDP-43 expression in 
patients and hopefully delay or cure TDP-43-linked patients.  
2.1.2.3 Drosophila FUS models 
The pathogenic mechanisms underlying FUS proteinopathy remain largely unknown, 
although it is clear that FUS mutations affects motor neurons and other neuronal 
populations such as cortical neurons. In order to study FUS related function in vivo, a 
FUS/TLS Drosophila model was generated in which targeted expression of mutant human 
FUS/TLS (R518K, R521C and R521H) caused severe neurodegeneration in Drosophila eyes, 
whereas expression of WT human FUS/TLS resulted in very mild eye degeneration 
(Lanson, et al., 2011). Locomotor dysfunction and premature lethality was also observed in 
the mutant FUS/TLS transgenic flies. In addition, overexpression of mutant FUS/TLS 
caused an accumulation of ubiquitinated proteins, a pathological hallmark feature of ALS. 
Similarly, a pathogenic role of human ALS-associated FUS/TLS mutations (R524S and 
P525L) using Drosiphila has been described (Chen, et al., 2011). In this model 
overexpression of either Wt or ALS-mutant in different neuronal subpopulations, including 
photoreceptors, mushroom bodies and motor neurons led to an age-dependent progressive 
neuronal degeneration, including axonal loss, morphological changes and functional 
impairment in motor neurons. The human FUS/TLS drosophila ortholog (caz) has been also 
disrupted in order to study FUS function. The caz deficient fly exhibited reduced life span 
and locomotor deficits as compared with controls. Interestingly, these phenotypes were 
fully rescued by WT human FUS, but not ALS-associated mutant FUS proteins suggesting 
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that ALS-associated FUS/TLS mutations are toxics (Walker, et al., 2011). Through cross-
rescue analysis, it has been demonstrated that FUS acted together with and downstream of 
TDP-43 in a common genetic pathway in neurons. Furthermore, the authors found that 
these proteins associated with each other in an RNA-dependent complex. These results 
establish that FUS and TDP-43 function together in vivo and suggest that molecular 
pathways requiring the combined activities of both of these proteins may be disrupted in 
ALS and FTD. 
2.2 Vertebrate models 
Projecting the human genome sequence into our understanding of human health and 
disease has been a new challenge faced in the post-genomic era. As described above, 
unicellular and invertebrate model systems can be of great value in defining the molecular 
components of pathways or processes that depend on the function of several interacting 
proteins. However, vertebrate models offer the best opportunity for defining landmarks of 
disease progression and for understanding the functional consequences of gene mutations. 
The great advantage of using vertebrates to model human diseases is clearly the possibility 
they offer for evaluation of new treatments. Indeed, testing new drugs on mice or other 
vertebrate models is often mandatory and asked by the Food and Drug Administration, for 
safety reasons, prior to approve new drug treatments. This step is also fundamental for 
paving the way towards human clinical trials, with both larger and smaller vertebrate model 
organisms. 
Other advantages of using vertebrate models include: the ability to make efficient targeted 
gene knockouts by homologous recombination, they are evolutionary closer to human, the 
developmental overview is similar for all mammals, the availability of material at all stages 
of development, their brains are more similar to human, they respond to injury and can be 
conditioned (great advantages to study learning, neuronal connectivity and plasticity) and 
they provide a valuable source of primary cells for culture. The later feature will be 
discussed in more details in the next section of this book chapter.  
On the contrary, the high maintenance cost, a relatively slow life cycle development, lower 
number of progeny, genetically identical offspring more difficult to obtain and the difficulty 
to manipulate embryos (intrauterine development) represent the major disadvantages of 
using vertebrate as disease model organisms. 
2.2.1 Mice 
Over the past century, the laboratory mouse (Mus musculus) has become the premier 
mammalian model organism for experimental studies and genetic research. Scientists from a 
wide range of biomedical fields have used the mouse because of its close genetic and 
physiological similarities to humans, as well as the ease with which its genome can be 
manipulated and analyzed, ease of handling and it’s relatively high reproductive rate. 
Although yeasts, worms and flies are excellent models for studying many developmental 
processes, mice are far better models for studying diverse physiological systems such as the 
immune system, the endocrine system, the nervous system, the cardiovascular system, the 
skeletal system and other complex physiological systems that mammals share. Like humans 
and many other mammals, mice naturally develop diseases that affect these systems, 
including cancer, atherosclerosis, hypertension, diabetes, osteoporosis and glaucoma. In 
addition, manipulating the mouse genome and environment can induce certain diseases that 
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afflict humans but normally do not strike mice, such as cystic fibrosis, obesity, blindness, 
anxiety, aggressive behavior, alcoholism, drug addiction and neurodegenerative disorders 
such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and ALS. 
Immunodeficient mice can also be used as hosts to facilitate cancer and AIDS research. 
Researchers have used a collection of innovative genetic technologies to produce custom-
made mouse models for a broad array of specific diseases, as well as to study the function of 
targeted genes. One of the most important technological advances has been the ability to 
produce transgenic mice, in which a new gene (cloned from human or other various species, 
wild-type or mutated) is inserted into the mouse's germline. Indeed, the 2007 Nobel Prize in 
Physiology and Medicine was awarded to Drs Mario R. Capecchi, Martin J. Evans and 
Oliver Smithies for their discoveries of principles for introducing specific gene modifications 
in mice by the use of embryonic stem cells. Even more potent approaches, it is now possible 
to knockout or to artificially drive the expression of an inserted gene in specific tissue or at 
various time during development or adulthood using the Cre/Loxp system (Sauer, 1998). 
There are many mouse models commercially available for genetic research including 
thousands of unique inbred strains and genetically engineered mutants. 
Researches using the laboratory mouse led to major advances in our ability to treat a 
number of serious diseases and conditions. Genetically, mice are more closely related to 
humans than invertebrates in the sense that most human genes have functional mouse 
counterparts and the mouse genome is organized in a very similar manner to the human 
genome. The mouse and human genomes are approximately the same size. They most likely 
contain the same number of genes and show extensive synteny and conserved gene order. 
Importantly, mice have also genes that are often not represented in other models, such as C. 
elegans and Drosophila. All these advantages make the laboratory mouse the model organism 
of choice to study human diseases. Although mice are widely used in research, questions 
remain however about their reliability as a model for human diseases. In occurrence, how to 
explain that many drugs worked well during preclinical trials in mice, but turned out to be 
ineffective when used in clinical trials on humans? Here, we will review the mouse studies 
that contributed toward understanding the pathogenic pathways of motor neuron disease 
and the testing of therapeutic approaches.  
2.2.1.1 Mice SOD1 models 
The use of mouse models has been of particular importance in studying the pathogenesis of 
Amyotrophic Lateral Sclerosis. The initial description of SOD1 gene mutations in familial 
ALS patients, in 1993, first led to the hypothesis that the disease resulted from compromised 
enzymatic activity due to the loss of the enzyme function (Rosen, et al., 1993). However, this 
loss of function hypothesis was rapidly refuted, as Sod1 KO mice in which the murine Sod1 
gene was disrupted, do not develop disease (Reaume, et al., 1996). To date, over 150 
different SOD1 missense mutations have been reported. In contrast, transgenic mice 
ubiquitously overexpressing various SOD1 gene mutations with different biochemical 
properties, even in the presence of endogenous mouse Sod1 gene, develop a 
neurodegenerative disease that is quite similar to the human illness. Of particular interest, 
transgenic mice overexpressing WT human SOD1 or specifically expressing mutant SOD1 
only in neurons or only in glial cells do not develop disease (Bruijn, et al., 1998; Gong, et al., 
2000; Pramatarova, et al., 2001). A toxic gain-of-function rather than a loss-of-function of 
mutant SOD1 gene is therefore believe to be involved in ALS-linked SOD1 patients. All 
published mouse models have used the endogenous murine Sod1 promoter resulting in high 
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levels of expression of the mutant transgene in all tissues. Although these models implicate 
mutant SOD1 in the development of motor neuron degeneration, many questions regarding 
the mechanism of pathogenesis remain unanswered. One of the central mysteries in ALS 
research is why an ubiquitously expressed gene such as SOD1 causes selective devastation 
to motor neurons in the absence of pathology in other tissues. One possible explanation is 
that expression of the mutant protein in motor neurons may not be sufficient to lead to the 
development of a neurodegenerative disease in mice, suggesting that mutant SOD1 
expression in other cells may be necessary for the development of the disease. Although 
there are indications that neurodegeneration in ALS may not strictly result from a cell-
autonomous process, the selective motor neuron vulnerability observed in the disease 
pathogenesis remains enigmatic. 
The favored hypothesis at this time of SOD1-mediated disease is that toxicity of SOD1 
mutants is related to the misfolding and aggregation of SOD1 species (Gros-Louis, et al., 
2009b). However, it is not clear which conformational SOD1 species and oligomers cause 
ALS and the exact mechanism of toxicity of the misfolded SOD1 species remains unknown. 
Deleterious effects could result from the interaction of misfolded SOD1 species with 
essential cellular components such as Bcl-2 (Pasinelli, et al., 2004), from their recruitment to 
outer membrane of mitochondria or from overwhelming the capacity of the protein folding 
chaperones and/or of ubiquitin proteasome pathway to degrade important cellular 
regulatory factors (Turner, et al., 2005; Urushitani, et al., 2008; Urushitani, et al., 2002). The 
misfolded SOD1 protein may also form aggregates that might sequester important cellular 
components causing cytotoxicity. Recent studies demonstrated that a fraction of SOD1 could 
be translocated via the ER-Golgi network and that chromogranins, which are abundant 
proteins in motor neurons, interneurons and activated astrocytes, may act as chaperone-like 
proteins to promote secretion of misfolded SOD1 mutants (Urushitani, et al., 2008; 
Urushitani, et al., 2006). Moreover, it has been reported that extracellular mutant SOD1 can 
induce microgliosis and motor neuron death (Urushitani, et al., 2006). Such ALS pathogenic 
mechanism based on toxicity of secreted SOD1 mutant is in line with findings that disease is 
not strictly autonomous to motor neurons and that toxicity can propagate from one cell to 
another. Interestingly, it has been proposed that endoplasmic reticulum (ER) stress response 
might exert a critical role in the disease pathogenesis. The ER is the site of synthesis and 
folding of secretory and membrane bound proteins. The capacity of the ER to process 
proteins is limited and the accumulation of misfolded proteins may activate different ER 
stress pathways. The challenges in the future are to find out which somatic insults are 
causing the initial protein change, and to discover ways of preventing the misfolded 
proteins from spreading through the nervous system. 
The overexpression of either G37R, G85R, G86R, D90A, G93A, H46R/H48Q or 
H46R/H48Q/H63G/H120G, L126Z and G127X mutant SOD1 protein in mice leads to motor 
neuron degeneration (Borchelt, et al., 1994; Bruijn, et al., 1997; Gurney, et al., 1994; Jonsson, 
et al., 2004; Jonsson, et al., 2006; Ripps, et al., 1995; Tu, et al., 1996; Wang, et al., 2003; Wang, 
et al., 2002; Wong, et al., 1995). In all of these mouse models, massive death of motor 
neurons in the ventral horn of the spinal cord and loss of myelinated axons in ventral motor 
roots ultimately leads to paralysis and muscle atrophy. Histopathological findings observed 
in these transgenic animals include progressive accumulation of detergent-resistant 
aggregates containing SOD1 and ubiquitin, aberrant neurofilament accumulations in 
degenerating motor neurons. In addition to neuronal degeneration, similar to that observed 
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in ALS patients, Golgi fragmentation and neuroinflammation noted by the presence of 
reactive astroglia and microglia in diseased tissue are also observed. However, the severity 
of the phenotype (in term of age of onset, disease progression and disease duration) varies 
from one model to another and may be dependant on mouse genetic background (Heiman-
Patterson, et al., 2005) and gene dosage. In deed, the life span of these ALS mice is inversely 
proportional to gene dosage, i.e. the number of transgene insertion within the mouse 
genome, leading to different steady state level of mutant SOD1 protein in the central 
nervous system. Such variation in the steady state protein levels must reflect different 
stabilities and degradation of the various human SOD1 mutants.  
The G93A-SOD1 mouse line is currently the most widely used experimental model in ALS 
research and drug testing. Unfortunately, several pharmacological approaches tested so far 
have produced only modest beneficial effects. Riluzole, a glutamate antagonist, extended 
the life span of G93A-SOD1 mice by 10 to 15 days without affecting disease onset (Gurney, 
et al., 1996). Today, riluzole is the only drug currently approved for ALS treatment.  This 
treatment only produces modest beneficial effect in some ALS patients. Interestingly, is has 
been shown that treatment with the ER stress-protective agent salubrinal attenuated disease 
manifestations and delayed progression in a G93A-SOD1 mouse model (Saxena, et al., 2006). 
This result suggests a role of ER stress in ALS. Furthermore, it has been also shown that 
immunization therapy, using specific anti-misfolded SOD1 monoclonal antibodies, 
succeeded in reducing the level of mutant SOD1 by 23% in the spinal cord of immunized 
animals, in delaying disease onset and in prolonging the lifespan of G93A-SOD1 mice in 
proportion to the duration of treatment (Gros-Louis, et al., 2010). These results suggest that 
accumulation of misfolded SOD1 species is toxic, and reducing the burden of these toxic 
species leads to beneficial effect. Interestingly, it has been recently reported that WT SOD1 
can acquire properties of ALS-linked mutant SOD1 species possibly implying a shared 
pathophysiological pathway between SALS and FALS (Bosco, et al., 2010b; Ezzi, et al., 2007). 
Another study also demonstrated that WT SOD1 may acquire toxic properties upon 
oxidative damage and that WT SOD1 expression dramatically exacerbated disease in 
transgenic mice expressing mutant SOD1 forms such as A4V, G85R, L126Z, and G93A SOD1 
mutants (Wang, et al., 2009b). It is noteworthy that overexpression of WT SOD1 conferred 
ALS disease to unaffected A4V SOD1 mice. Based on these results, the possibility that WT 
SOD1 may be a contributor of pathogenesis in sporadic ALS must be considered. 
2.2.1.2 Mice TDP-43 models 
As previously mentioned, several research groups have reported that dominant mutations 
in the TARDBP gene, which encodes for TDP-43, cause ALS (Kabashi, et al., 2008; 
Sreedharan, et al., 2008; Van Deerlin, et al., 2008). Following these initials studies, a number 
of TDP-43 ALS mouse model has been described. Embryonic lethality is observed in 
homozygous mouse knockouts for TDP-43 (Kraemer, et al., 2010; Sephton, et al., 2010; Wu, 
et al., 2010). The TDP-43 deficient embryos die at embryonic day 7.5 thereby demonstrating 
the essential function of TDP-43 protein in development. Mice heterozygous for TDP-43 
disruption only exhibit subtle muscle weakness with no evidence of motor neuron 
pathology. 
Many of the transgenic mouse lines overexpressing WT or mutant TDP-43 reported to date 
have showed some ALS features including early paralysis leading to premature death 
(Stallings, et al., 2010; Wegorzewska, et al., 2009; Wils, et al., 2010). These pan-neuronal TDP-
43 transgenic mouse models expressing high-level of either WT or mutant (A315T and 
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M337V) TDP-43 transgene in neurons both showed aggressive paralysis accompanied by 
increased ubiquitination in specific neuronal populations (Stallings, et al., 2010; 
Wegorzewska, et al., 2009; Wils, et al., 2010; Xu, et al., 2010).  However, many concerns have 
been raised regarding the biological validity of these models, as they do not completely 
mimics disease. Since TDP-43 is a moderately and ubiquitously expressed protein, restricted 
non-physiological neuronal expression of TDP-43 is one of them, along with the use of the 
TDP-43 cDNA as transgene and the lack of cytoplasmic ubiquitinated TDP-43 inclusions. In 
order to better mimic the ubiquitous and moderate levels of TDP-43 expression seen in 
humans, another transgenic mouse models have been generated allowing the expression of 
genomic TDP-43 fragments (Swarup, et al., 2011). This TDP-43 mouse model exhibited age-
related phenotypic defects as seen in the human condition including both cognitive and 
motor deficits. Other pathological features as seen in human patients were also observed 
including, cytoplasmic TDP-43-positive ubiquitinated inclusions, intermediate filament 
abnormalities, axonopathy and neuroinflammation. These phenotypes were more severe in 
the transgenic TDP-43 mutant (G348C and A315T) models than the transgenic TDP-43 WT 
model. 
2.2.1.3 Mice intermediate filament models 
Several transgenic mouse lines and knockout mice implicating different neurofilament 
subunits have been extensively studied over the past years (for complete review, see: (Julien 
and Kriz, 2006; Lariviere and Julien, 2004)). Even though genetic mutations in intermediate 
filament (IF) genes are not major causes of ALS, it is of potential relevance to ALS that 
transgenic mice with altered stoichiometry of neuronal intermediate filament develop 
pathological features of the disease (Beaulieu, et al., 2000; Beaulieu and Julien, 2003; Cote, et 
al., 1993; Millecamps, et al., 2006). Of particular interest was the finding that overexpression 
of WT peripherin, a type III intermediate filament, in NEFL null background mice caused 
age-dependant selective motor neurons degeneration (Beaulieu, et al., 1999). This mouse 
model is also characterized by the formation of perikaryal and axonal intermediate filament 
inclusions resembling spheroids in motor neurons of human ALS. The precise mechanism 
by which accumulation of intermediate neurofilament leads to neurodegenerative disorders 
is not fully understood. Neurofilament and peripherin proteins are two types of 
intermediate filaments detected in the majority of axonal inclusion bodies, called spheroids, 
in motor neurons of ALS patients (Corbo and Hays, 1992). Multiple factors can potentially 
cause the accumulation of intermediate filament proteins including deregulation of 
intermediate filament protein synthesis, proteolysis, defective axonal transport, abnormal 
phosphorylation, and other protein modifications.  
2.2.1.4 Mice ALS2 models 
Truncating mutations were discovered in coding exons of a the ALS2 gene encoding for 
Alsin, from patients with an autosomal recessive form of juvenile ALS, primary lateral 
sclerosis (PLS) and infantile-onset ascending hereditary spastic paralysis (IAHSP) (Devon, et 
al., 2003; Eymard-Pierre, et al., 2002; Eymard-Pierre, et al., 2006; Gros-Louis, et al., 2003; 
Hadano, et al., 2001; Kress, et al., 2005; Yang, et al., 2001). The pattern of inheritance and the 
nature of the mutations identified in this gene suggest that motor neuron degeneration seen 
in patients results from a loss of protein function. Six different groups have reported the 
generation of an alsin knockout mouse (Cai, et al., 2005; Deng, et al., 2007; Devon, et al., 
2003; Gros-Louis, et al., 2008; Hadano, et al., 2006; Yamanaka, et al., 2006). Despite an age-
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dependent loss of motor coordination revealed by rotarod and grip strength performances 
of the Als2 KO mice, no major motor deficits consistent with ALS or other motor neuron 
diseases were present in these models. All Als2-deficient mice appear to be grossly normal, 
viable and fertile with lifespan expectancy similar to WT littermates. However, some 
differences are noteworthy and may explain the heterogeneity of the phenotype, ranging 
from ALS to less severe PLS or IAHSP. The diversity of the apparent phenotypes among 
different Als2 KO mouse models may be due in part by different gene targeting strategies 
used to generate each mice models, ES cell lines used leading to differences in the genetic 
background, housing conditions or approaches taken to evaluate the mice.   
Interestingly, thorough molecular analysis of one of these Als2 KO mouse model revealed 
the presence of a number of novel Als2 isoforms expressed in the central nervous system of 
these animals (Gros-Louis, et al., 2008). These results suggest that other alternatively spliced 
Als2 isoforms may exist and that some of these novel Als2 mRNA species still can be 
transcribed in Als2 null animals and may compensate for the loss of the full-length protein.  
2.2.1.5 Mice models associated with other motor neuron diseases 
Different other transgenic mice models overexpressing different human proteins either 
ubiquitously or specifically in neurons have been generated (for review see (Gros-Louis, et 
al., 2006; Julien and Kriz, 2006). These mice acquire age-dependent central nervous system 
pathology similar to other related motor neuron diseases such as FTDP17, progressive 
supranuclear palsy, spinal muscular atrophy or hereditary spastic paraplegia. Interesting 
pathological features, which are also associated with ALS, can be seen in these different 
mouse models including axonal degeneration in brain and spinal cord, progressive motor 
disturbance, behavioral impairment, and the presence of cellular aggregates and 
intermediate filament inclusions. 
2.2.2 Rat 
As a model of human disease, the laboratory rat (Rattus norvegicus) offers some advantages 
over the mouse and other organisms. The main advantage is in fact that rats are 
physiologically more similar to humans compare to mice. The size of the animal also confers a 
valuable advantage and enhances its use as a disease model. The later advantage is especially 
true when performing surgical procedures, microdialysis, intravenous cannulation and for 
pharmacodynamic drug studies as its size enables serial blood sampling. Thereby, the rat 
would be a better model than the mouse to study cardiovascular disease, hypertension, 
diabetes, arthritis, and many autoimmune, behavioral, and addiction disorders. The rat is also 
a good model in neurobehavioral and stereotaxic neurological studies. The size of the rat brain 
offers unique possibilities for the application of microsurgical techniques, intrathecal 
administration of drugs, stem cell transplantation, serial sampling of the cerebrospinal fluid 
(CSF), in vivo nerve recordings, and neuroimaging procedures.  
However, even though its size is considered as an advantage over mice, the higher cost of 
maintenance (bigger cages, food, less animals can be housed per cages) and limited housing 
capacity in animal facilities directly related to its size also confers the principal limitation of 
using rats as a model.  
2.2.2.1 Rat SOD1 models 
Transgenic rat models of ALS have also been generated.  In these models overexpression of 
G93A or H46R mutant SOD1 led to an ALS-like phenotype (Howland, et al., 2002; Nagai, et 
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al., 2001). These transgenic rat models reproduce the major phenotypic features of human 
ALS, such as selective motor neuron loss, ubiquitination, hyaline inclusions, vacuolation, 
and neuroinflammation. However, several differences between the rat and mouse ALS 
models can be denoted including a more rapid progression of disease and the transient 
appearance of vacuoles in the transgenic SOD1 rats. As the CSF volume of a rat is 10- to 20-
fold greater than that of a mouse (Nagai, et al., 2001), transgenic SOD1 rats may facilitate to 
study the CSF proteome and to detect SOD1 activity or drug concentrations, even in an age-
dependent manner. Therefore, ALS rat models may be useful to demonstrate therapeutic 
efficacy, blood-brain barrier filtration and to assess the toxicity of novel therapeutic 
compounds in drug development. 
2.2.2.2 Rat TDP-43 models 
In order to generate a TDP-43 rodent model that is more suitable for pharmacological 
studies, rat models ubiquitously overexpressing either WT TDP-43 or the M337V-associated 
TARDBP mutation were generated (Zhou, et al., 2010). In contrast to what it is observed in 
TDP-43 transgenic mouse models, overexpression of mutant TDP-43 only, but not the WT 
protein, caused widespread neurodegeneration. Despite the fact that this transgenic mutant 
TDP-43 rat model exhibited progressive degeneration of motor neurons, neurodegeneration 
was not only restricted to motor neurons. However, TDP-43 mutation affected motor 
neurons earlier and more severely than other neurons in the CNS at end stage of the disease. 
In some aspects, this rat model recapitulated TDP-43 pathological features both seen in the 
different mouse models and in ALS patients indicating that this model could be used in 
future pharmalogical studies in order to identify novel therapeutic avenues to treat TDP-43 
related disorders. 
2.2.3 Zebrafish 
In the last decade, a new vertebrate model has emerged in the study of human diseases.  The 
principal attraction of using zebrafish (Danio renio) as model organisms is that its genome 
can be much more easily manipulated and studied in terms of genetics and development 
than other vertebrate model organisms. As being a vertebrate with common organs and 
tissues with conserved organization such as brain and spinal cord, the attractiveness of 
zebrafish to model human diseases lies therefore in its biology and genetics. Although there 
are obvious differences in the physiology of fish and humans the zebrafish offers several 
advantages that make it an important complement to mouse models of disease. These 
advantages include the embryo and larvae optical clarity (which allows easy visualization of 
developmental processes), the external fertilization (which facilitates gene expression 
manipulation), high fecundity (adult female can lay hundreds of eggs per day), and rapid 
development (swimming behavior appears less than 48 hours post-fertilization). As in 
invertebrate models, it is also relatively easy to perform forward and reverse genetic screens 
for gene identification and to understand specific gene function. 
Forward-genetic screens in zebrafish, using random mutagenesis, can be used to identify 
novel genes involved in embryogenesis, organogenesis or different specific biological 
processes. To generate mutants, male fish are exposed to the mutagen ethyl-nitroso-urea 
(ENU), which typically induces point mutations within zebrafish genome (Driever, et al., 
1996; Haffter, et al., 1996; Henion, et al., 1996; Solnica-Krezel, et al., 1996). Random 
mutagenesis has also been successfully carried out in zebrafish using retroviral methods 
(Amsterdam, et al., 1999). Treated males are then crossed to wildtype females to produce the 
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F1 heterozygous progeny and so on so forth in order to generate homozygous progeny and 
to facilitate the identification of gene mutation by positional cloning. Forward-genetic 
screens in zebrafish are greatly facilitated by the transparency of embryos and larvae, 
simplifying phenotypic screening and allowing large scale screening without sophisticated 
expansive equipments. These features provide an advantage over other vertebrate models in 
which aspects of organogenesis and disease pathology cannot be examined without surgical 
interventions. Large-scale forward-genetic screens have allowed the identification of 
numerous mutations in zebrafish genes (Amsterdam and Hopkins, 2006). Comparative 
genomic can be then used in order to identify the corresponding orthologous gene in 
humans and, in some instances, the mutant phenotypes have been sufficiently similar to the 
human pathology to allow the identification of gene mutations by a candidate gene 
approach.  
On the other hand, reverse genetics refers to the study of the phenotypic consequences 
following manipulation of gene expression. An essential tool for investigating gene function 
during development is the ability to perform gene knockdown, overexpression, and 
misexpression studies. The external egg fertilization in zebrafish enables microinjection of 
RNA, DNA, proteins, antisense oligonucleotides and other small molecules into the 
developing embryo thereby providing researchers a quick and robust assay for exploring 
gene function in vivo. Antisense morpholino oligonucleotides (AMO) are now widely used 
to modify gene expression by blocking translation of a targeted protein or by modifying pre-
mRNA splicing (Nasevicius and Ekker, 2000)). The ability to examine the course of a 
pathological process in vivo and in real time using AMO reverse genetic is a particular 
strength of zebrafish models. In particular, AMO are powerful reverse genetic tools for the 
biological validation of genetic variants identified in human and for defining the 
pathological nature of a particular gene mutation (Amsterdam and Hopkins, 2006). Finally, 
high-throughput screening for small-molecule chemical able to modify disease 
pathogenesis, firmly establishing a role for zebrafish in the field of pharmaceutical drug 
discovery. 
2.2.3.1 Zebrafish SOD1 models 
In order to generate a SOD1 zebrafish model of ALS, transient overexpression of human 
SOD1 mutants (A4V, G37R and G93A) was achieved using mRNA microinjection into 2 to 4 
cell stage blastulae (Lemmens, et al., 2007). Overexpression of mutant human SOD1 in 
zebrafish embryos induced a dose-dependant motor axonopathy in all studied mutations. 
Likewise in ALS patients, ubiquitous expression of the mutant protein produced motor 
neuron specific neuropathology, suggesting that this model may be useful to elucidate the 
mechanisms underlying specific vulnerability of motor neurons in SOD1-linked ALS. 
Interestingly, the observed motor neuron phenotype in this transient SOD1mutant zebrafish 
embryo expresser suggests that ALS may be a developmental disease.  
With the goal of achieving constitutive mutant SOD1 expression in zebrafish, Ramesh and 
colleagues generated transgenic zebrafish models overexpressing either WT or mutant 
SOD1 (Ramesh, et al., 2010). Zebrafish overexpressing mutant SOD1 exhibited many 
hallmark phenotypes of ALS including neuromuscular junction defects, spinal motor 
neuron loss, muscle degeneration, decreased endurance to swim, partial paralysis and 
premature death. Interestingly, all of these pathological features are consistent with those 
seen in SOD1 transgenic mice and rats, supporting the idea that overexpression of SOD1 in 
vertebrate models results in the development of common pathologies. As zebrafish are 
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highly amenable to chimeric analysis, this zebrafish model will offer a tool to hopefully 
address in future studies the cell autonomous hypothesis seen in SOD1-linked ALS.   
2.2.3.2 Zebrafish TDP-43 models 
In order to test the toxicity associated with various TARDBP mutations (A315T, G348C and 
A382T), transient overexpression of WT and mutant TDP-43 was achieved by TARDBP 
mRNA microinjection (Kabashi, et al., 2010). Mutant TDP-43 overexpression resulted in 
motor neuron defects, including shorter axons, abnormal axonal branching and swimming 
deficits in the absence of sensory deficits. These phenotypes were also observed in WT 
TARDBP overexpressing zebrafish, but were less severe. These results confirmed that the 
studied TARDBP mutations are toxic and suggested that TDP-43 linked mutations 
preferentially target motor neurons for degeneration. Interestingly, knocking down the 
zebrafish Tardbp gene (zTardbp), using a specific AMO designed to block zTardbp translation, 
led to a similar phenotype, which was rescued by co-expressing WT but not mutant human 
TDP-43 (Kabashi, et al., 2010). Together these two reverse genetic approaches showed that 
TARDBP mutations cause motor neuron defects and toxicity, suggesting that mutant TDP-
43 contributes to disease pathogenesis by both a toxic gain-of-function and a loss-of-function 
molecular mechanisms. 
2.2.3.3 Zebrafish FUS models 
To test the FUS/TLS-linked mutations toxicity, transient expression of mRNAs encoding 
green fluorescent protein (GFP)-FUS (WT, H517Q, R521G, R495X or G515X) fused proteins 
was achieved by injecting these mRNA into zebrafish eggs at the 1 to 2 cells stage of 
development (Bosco, et al., 2010a). Interestingly, the expression of human FUS WT and the 
H517Q and R521G mutants each exhibited a predominantly nuclear pattern in the spinal 
cord, whereas the R495X and G515X truncation mutants accumulated in the cytoplasm. 
Noteworthy, abnormal accumulation of protein in the cytoplasm has been frequently 
observed in post-mortem tissues collected from ALS patients. This phenotype was 
exacerbated after heat shock treatment. These results suggest that the studied FUS-linked 
mutations induce toxicity and that multiple factors may influence the subcellular 
localization of GFP-FUS in vivo, including various cellular stresses. Similarly, upon transient 
overexpression of a FUS-linked ALS mutation (R521H) in zebrafish embryos, motor deficits 
characterized by abnormal touch-evoke escape response was observed in 57% of the mRNA 
injected zebrafish larvae as compared to 23% in controls (Kabashi, et al., 2011). These results, 
from both studies, indicate that ALS-linked FUS/TLS mutants can cause motor neuron 
deficits by a toxic gain-of-function. On the other hand, loss-of-function cannot be totally 
excluded as knockdown of the zebrafish Fus (zFus) gene, using antisense morpholino oligo, 
also yielded a motor phenotype characterized by a deficient touch-evoked escape response, 
reduced motor neuron outgrowth and axonal branching (Kabashi, et al., 2011). Interestingly, 
these phenotypes could be rescued upon co-expression of WT human FUS but not ALS-
linked FUS/TLS mutations. 
2.2.3.4 Zebrafish ALS2 models 
To investigate ALS2 gene function and to elucidate if the identified mouse Als2 splicing 
isoforms may compensate for the loss of the full length protein in Als2 KO mice described 
earlier, a knock-down of the zebrafish Als2 ortholog (zAls2) in zebrafish was performed 
using an AMO directed against the start codon of the zAls2 gene (Gros-Louis, et al., 2008). 
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Consistent with this hypothesis, Gros-Louis and colleagues found that the zAls2 knocked 
down zebrafish led to both severe developmental abnormalities and an obvious behavioral 
phenotype, including swimming impairment and motor neuron disruption.  This model is 
still the only ALS2 animal model mimicking the severe motor neuron degeneration 
observed in ALS2 patients. Interestingly, some of these Als2 splice variants rescued the 
zebrafish phenotype suggesting that these identified spliced variants, observed in Als2 null 
mice and in ALS2 patients, prevented the Als2 KO mice from developing severe 
neurodegenerative disease. These findings may also explain the variable phenotype 
observed in ALS2-linked patients. 
2.2.4 Dog 
The domestic dog (Canis familiaris), with over 450 naturally-occurring hereditary diseases, is 
a valuable model organism for the study of human genetic diseases and complex traits. In 
humans, common diseases show complex modes of inheritance, and as a result, genetic 
analysis and gene mapping could be tedious. Rodent systems are more tractable genetically, 
but studies using transgenic mouse models represent an induction of a particular mutation 
rather than naturally arising alleles, and results are often of limited direct relevance to 
human disease because of profound differences in physiology. In contrast, the physiology, 
disease presentation and clinical response of dogs to drugs often mimic human diseases 
closely. The dog genome is similar in size to the human genome; containing an estimated 2.8 
billion DNA base pairs (Lindblad-Toh, et al., 2005). Canine models have played an 
important role in advancing biomedical knowledge and techniques. Due to a long history of 
selective breeding, many breeds of dogs are naturally prone to genetic diseases including 
cancer, autoimmune and neurological disorders afflicting humans. These dog models, in 
which naturally occurring mutations in different genes was described, may help the study 
of genetic diseases difficult to study in humans. The structure of the canine population 
offers specific advantages for genetic mapping studies. The dog enjoys a genetic diversity 
unrivaled by any other mammalian species. A thousand centuries of directed breeding by 
humans has been responsible for that diversity leading to an unequaled variety of 
morphologies and behaviors, and also into a number of inherited diseases. The top 10 
diseases in dogs include cancer, epilepsy, allergy, retinal disease, cataracts, and heart 
disease. Several of these diseases constitute also a major health concerns to humans. 
The disadvantages of using dog as a model are its size, cost of maintenance and housing 
limitations in order to provide adequate area for the dogs to run. Furthermore, there use in 
research has been more controversial and of public concerns than other animal models 
because of an obvious emotional tie toward dogs.  
2.2.4.1 Dog SOD1 model 
A genome-wide association analysis reveals a SOD1 mutation in canine degenerative 
myelopathy (Awano, et al., 2009). This disease has been recognized for more than 35 years 
as a spontaneously occurring, adult-onset spinal cord disorder of dogs (Averill, 1973). The 
resequencing of the canine Sod1 gene revealed a recessive E40K missense mutation. 
Pathological studies of spinal cords from affected dogs showed myelin and axonal loss, 
SOD1-positive neuronal cytoplasmic inclusions similar to those seen in patients. The disease 
is also fatal in dogs and, typically, presents with progressive upper motor neuron spasticity 
and general proprioceptive ataxia in the pelvic limbs leading to paraplegia.  Dogs develop 
disease generally around 8 years of age or older and disease duration will not exceed, if 
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euthanasia is delayed, 3 years. These findings suggest that this disease afflicting dogs is 
closely related to ALS and identify canine degenerative myelopathy to be the first 
recognized spontaneously occurring animal model for ALS. The canine ALS model may be 
particularly valuable for evaluating therapeutic interventions as the environmental 
conditions and the SOD1 level of expression mimic better the human ALS situation. 
2.2.5 Pig 
Pigs, although not easily kept for laboratory research, are readily available for biomedical 
research through the large-scale industrial production of pigs produced for human 
consumption. Recent research has facilitated the biological experimentation with pigs, and 
helped develop the pig into a novel model organism for biomedical research. 
The domesticated pig (Sus scrofa) shares several similarities with human, in particular the 
size of organs and various aspects of anatomy and physiology. The development of somatic 
cloning technology and the merger with techniques of targeted genetic modification and 
conditional gene expression will enhance the possibilities for creating useful models for 
human diseases in pigs. The pig has also evolved as the major target species for producing 
xenografts in order to provide appropriate human organs. The sequencing of the domestic 
pig genome has not yet been fully completed. However, initial draft revealed that the size 
and composition of the porcine genome is comparable to that of humans; comprising about 
2.7 billion base pairs (Hart, et al., 2007). Furthermore, both gene content and sequence are 
highly conserved between pig and human. Detailed information on the porcine genome 
together with emerging transgenic technologies, such as siRNA or conditional knockouts 
will enhance our possibilities to create useful pig models. Other advantages of using 
domestic pigs to model human diseases include high fertility, great abundance, rapid 
growth, anatomy and physiology not too different from human and the possibility to 
introduce genetic modifications in its genome.  The pig has been an essential and very 
successful model in biomedical research and is particularly suited to close the gap between 
basic research in current models and clinical application. The future will certainly see 
several promising porcine models for human diseases. 
The high resemblance between the central nervous systems of humans and pigs makes the 
pig an ideal model organism for studying human neurodegenerative diseases. For 
neurodegenerative disorders such as ALS, Parkinson’s disease and Alzheimer’s disease, the 
pig may represent a model superior to other models presently available. Large animals, 
including pigs and non-human primates in neuroscience enable the use of conventional 
clinical brain imaging and the direct testing of surgical procedures. The evaluation of novel 
therapeutic avenues in an animal model with higher brain complexity will allow a more 
direct translation to human diseases. 
3. In vitro models to study ALS 
In vitro models are extremely helpful to study human diseases because they allow to analyze 
different cell types independently from each other and to perform dynamic studies on 
isolated cells. Moreover, diseased cells can be combined with healthy ones to better 
understand which cell type is the most critical in the different stages of the disease. 
Some of these in vitro models were developed using the ALS animal models previously 
discussed. However, neural cells are impossible to obtain from patients and their extraction 
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from post-mortem tissues is limited due to the difficulty to isolate living cells from adult 
brain or spinal cord, especially motor neurons. 
Thus, such postmortem tissue biopsies are mostly used to perform histological and 
immunohistochemical, genetic as well as proteomic studies. More recently, they were also 
used to extract neural precursor cells that were further differentiated into motor neurons 
and glial cells to develop innovative models of the disease. 
3.1 Organotypic cultures of spinal cord slices 
The best way to preserve all the cellular content and the complex electrophysiological and 
biochemical organization of cells in the spinal cord is to maintain a whole tissue slice in an 
organotypic culture. In addition, organotypic slice cultures can be obtained from both 
embryos and postnatal animals, conferring a major advantage when using transgenic mice 
from which the disease genotype has to be ascertained after birth (Kosuge, et al., 2009; 
Mazzone and Nistri, 2011). After dissection of the lumbar spinal cord and removal of the 
meninges, 200 to 400µm-thick transversal sections are sectioned and transferred into 
membrane inserts fitting six-well or 12-well culture plates (Caldero, et al., 2010). These 
organotypic cultures can be used for more than 2 months (Delfs, et al., 1989). Various types 
of molecules can be added in the culture medium, such as kainate or lithium, to modulate 
neurotoxicity (Caldero, et al., 2010; Mazzone and Nistri, 2011). 
These tissue sections can then be used to perform various analysis like recording the neuron 
rhythmic activity by placing the tissue on a multielectrode array (Tscherter, et al., 2001; Young, 
et al., 2007), or studying real-time glutamate release using a biosensor and redox reaction 
current using a multichannel potentiostat (Mazzone and Nistri, 2011), in addition to the 
conventional immunohistochemical staining and electrophysiological recordings (Caldero, et 
al., 2010; Young, et al., 2007). Neonatal brainstem slices can be used to analyze excitotoxicity on 
hypoglossal motor neurons that control the respiratory drive. These neurons are particularly 
useful for electrophysiological studies because they exhibit a range of rhythmic patterns that 
will be altered during early onset of ALS (Cifra, et al., 2011a; Cifra, et al., 2011b). 
Organotypic culture is a convenient culture system that closely reproduces the in vivo 
situation and allows dynamic studies with various drugs and useful analysis systems. 
However, it does not always fully recapitulate what is happening in vivo (Tovar, et al., 2009). 
In addition, it does not easily allow the study of different mixed cell combinations by 
removing or by adding specific cell types to the tissue slices. These organotypic spinal cord 
slice cultures are difficult to obtain from postmortem patients due to limited availability and 
it is obviously impossible to study disease progression using human spinal cord biopsies as 
opposed to biopsies obtained from animal models. 
3.2 Spinal cord cell cultures 
The isolation of individual cells is extremely useful to study various intracellular mechanisms 
from proliferation to mRNA expression, mitochondrial function, protein aggregation, 
intermediate filament assembly or axonal transport. However, neurons cannot proliferate and 
are difficult to maintain in culture. In addition, adult nervous tissues are difficult to access and 
the viability of the cells extracted from them is very low. Actually, most of the cells that can be 
maintained in culture after extraction are neural precursor cells (Haidet-Phillips, et al., 2011).  
To overcome this limitation, embryos are preferred for nervous tissue harvesting. Indeed, at 
the E12-13 embryonic developmental stage, the spinal cord of mice embryos is easy to access 
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and remove, and motor neurons, astrocytes and microglia can be extracted, purified and 
maintain in culture with high viability yields (Gingras, et al., 2007b; Sanelli, et al., 2007; 
Schnaar and Schaffner, 1981). These cells can be dissociated from the spinal cord and 
cultured together to facilitate motor neuron survival (Tradewell, et al., 2011; Tradewell and 
Durham, 2010). Motor neurons will be easy to identify because of their large cell body 
(>20µm in diameter) and dendritic trees, and can be stained for expression of the 
transcription factor Hb9 and choline acetyltransferase, specific molecular markers of motor 
neuron (Fig 3) (Gingras, et al., 2007b; Tradewell, et al., 2011).  
 
 
Fig. 3. E12 mouse embryo-purified motor neurons. 
A: phase contrast microscopy of purified motor neurons 24h after seeding. B: Motor neurons 
were labeled in red with Hb9 and in green with MAP2. Bar represent 30 μm in A and 50µm 
in B. Courtesy of Dr. Marie Gingras. 
Cultures of purified motor neurons without the trophic support of glial cells are difficult to 
maintain for more than 2 weeks (Bar, 2000; Lunn, et al., 2009). In order to perform studies on 
a chronic disease like ALS, especially while looking for long-term cell survival effects, 
dissociated spinal cord cell cultures constitute a better choice as they can be maintain in 
culture for up to 7 weeks (Tradewell, et al., 2011). Purified motor neurons can also be 
cultured on an astrocyte feeder layer for several weeks on which they display characteristics 
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(neurite pattern) closer to adult motor neurons (Bar, 2000). To reproduce an ALS phenotype, 
motor neurons can be induced to express multiple copies of the gene of interest, for 
example, mutated human G93A SOD1, by microinjection of the vectors into the cells 
identified by their specific morphology (Tradewell, et al., 2011; Tradewell and Durham, 
2010). Motor neurons can also be purified and cultured separately, to allow their adenoviral 
transduction with G93A SOD1 (Lunn, et al., 2009), and then, to enhance their survival, they 
can be plated on a glial cell feeder layer treated with arabinofuranosyl cytidine (AraC), to 
prevent cell proliferation (De Paola, et al., 2008). These in vitro cultures are particularly 
useful to study cellular morphometry (axon length), gene expression using RT-PCR (ideally 
with only one purified cell type), apoptosis, signaling pathways, calcium imaging, 
mitochondrial membrane potential, glutamate uptake, excitotoxicity, etc.   
The major drawbacks of spinal cord cell cultures are the need to perform cell extraction from 
embryos for each new experiment. In addition, cells cultured on plastic dishes cannot 
recapitulate the in vivo environment and some results obtained in vitro may not be reproducible 
in vivo at least in part because the complex interactions developed in the nervous system are 
lost. Furthermore, another disadvantage to use primary cells from embryos is that some 
features of the adult phenotype may not be expressed at this early stage (Park, et al., 2004).  
3.3 NCS-34 motor neuron cell line 
To greatly facilitate in vitro studies, motor neuron-enriched embryonic mouse spinal cord 
cells were fused with mouse neuroblastoma to generate the hybrid cell line NCS-34 
(Cashman, et al., 1992; Durham, et al., 1993; Hunter, et al., 1991). This cell line contains small 
proliferative and undifferentiated cells and larger multinucleate cells. These cells express 
properties of motor neurons such as choline acetyltransferase, acethylcholine synthesis and 
neurofilament expression. They respond to agents affecting voltage-gated ion channels, 
cytoskeletal organization and axonal transport similarly with primary motor neurons, but 
failed to reproduce synaptic connections (Durham, et al., 1993). This cell line is widely used 
in several studies related to ALS (Foran, et al., 2011; Tabata, et al., 2008; Vijayalakshmi, et al., 
2009; Yang, et al., 2010). For example, NCS-34 cells were treated with the cerebrospinal fluid 
(CSF) collected from sporadic ALS patients. It induced intracellular aggregates formation, 
ubiquitin immunoreactivity, neurofilament phosphorylation and choline acetyl transferase 
expression through induction of endoplasmic reticular stress. This effect was attenuated by 
addition of VEGF prior to exposition to CSF (Kulshreshtha, et al., 2011; Vijayalakshmi, et al., 
2011; Vijayalakshmi, et al., 2009). NCS-34 cells can also be used to screen antioxidant 
molecules capable of rescuing them from expression of mutated SOD1 (Barber, et al., 2009). 
3.4 Xenopus oocyte model for electrophysiological recordings 
The Xenopus Laevi is an African frog from which the oocyte (egg) is a commonly used model 
for electrophysiological recording because of its large size (about 1mm in diameter) which 
facilitates its handling. The oocyte has been used for decades to study various ion channels, 
transporters and receptors. This cell can be transduced with a molecules of interest for co-
expression studies including the human glutamate transporter GLT1 (EAAT2) or NMDA 
receptors (Boehmer, et al., 2006; Texido, et al., 2011; Trotti, et al., 2001). This model has been 
used in some studies related to ALS, such as the analysis of the properties of the GLT1 
transporter activities under controlled voltage clamp in presence or not of mutant SOD1 
(Trotti, et al., 1999). 
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3.5 Neural precursor cells (NPCs) and induced pluripotent stem cells (iPS) 
One important advantage of in vitro cell cultures could gain over animal models would be to 
collect neural precursor cells directly from patients. These cells can be differentiated into all 
neural cell types, including motor neurons. As previously discussed, most of animal and cell 
culture models developed to study ALS so far were derived from known FALS-associated 
mutations in the SOD1, TARDBP or FUS/TLS genes. While these models are particularly 
useful to study FALS, they are not ideal for the study of SALS. Therefore, trying to 
understand the cause of the disease through the study of motor neurons and glial cells 
obtained from SALS patients would be challenging but potentially highly promising. 
However, motor neurons, and even glial cells are extremely difficult to isolate from brain 
and spinal cord samples obtained from post-mortem ALS patients. 
 
 
Fig. 4. Characterization of neural precursor cells (NPCs) extracted from postmortem ALS 
patient’s spinal cord.  
Cells express Iba1 (a marker of microglia) and 3-tubulin (early marker of neuronal 
differentiation) (A), Vimentin (transiently expressed in neuronal precursors) (B), Nestin 
(transiently expressed in neuronal precursors) (C) and Islet-1 (an early marker for motor 
neuron differentiation) (C) that highlight their NPC status when co-expressed together in 
the same cells. Courtesy of Dr. Marie-Josée Beaulieu. 
One very promising alternative is to take advantage of the neural precursor cells that can be 
extracted from adult tissues. Indeed, in a first step, the potential of mouse embryonic stem 
cells (ESCs) to differentiate into motor neurons has been well established (Wichterle, et al., 
2002) and applied to the development of in vitro ALS models using ALS-linked G93A SOD1 
gene mutation and WT SOD1 mouse embryos as source of stem cells (Di Giorgio, et al., 
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2007). It was shown that G93A-SOD1 ESCs differentiated into motor neurons had a lower 
survival over 2 to 4 weeks in culture than their WT counterparts and showed ALS pathology 
hallmarks such as SOD1 protein aggregates and increase in activated caspase-3 expression 
after 21 days of culture (Di Giorgio, et al., 2007). Motor neurons have also been successfully 
differentiated from human ESCs (Hester, et al., 2011; Hu and Zhang, 2009). However, to 
obtain a source of multipotent stem cells from adult ALS patients, other approaches needed 
to be developed. These cells can be obtained from easily accessible tissues such as skin 
(Gingras, et al., 2007a; Toma, et al., 2001), but their limited proliferation capacity in vitro 
needs a relatively large amount of starting materials that up to now preclude their extraction 
from patients. Another possibility is to obtain postmortem biopsies of brain and spinal cord 
from ALS patients. It has been shown that if living glial cells and neurons are difficult to 
isolate from these tissues, neural precursor cells (NPCs) with a good proliferation rate are 
oppositely easy to purify and culture in vitro. These cells can then be differentiated in the 
cell type of interest. Neurons, astrocytes and oligodendrocytes were differentiated from 
NPCs purified from familial and sporadic ALS patient postmortem spinal cord samples (Fig 
4) to study the toxic properties of patients-derived astrocytes on motor neurons (Haidet-
Phillips, et al., 2011). Both FALS and SALS-derived astrocytes were shown to be toxic to 
motor neurons, and the knock-down of SOD1 in SALS-derived astrocytes was demonstrated 
to attenuate this toxicity (Haidet-Phillips, et al., 2011). But postmortem tissues are difficult to 
obtain.  
A much more versatile technique to generate multipotent stem cells from adults is to 
generate induced pluripotent stem cells (iPS cells) starting from somatic cells. This technique 
only requires a small punch biopsy of a few millimeters in diameter collected from the 
patient’s skin, which will heal spontaneously without scarring. From this biopsy, dermal 
fibroblasts will be extracted and expanded to generate iPS cells. Generation of IPs cells is 
possible via overexpression of a defined set of transcription factors (c-Myc, Oct3/4, Klf4 and 
SOX2) (Takahashi, et al., 2007a; Takahashi, et al., 2007b). The genetic transduction of these 
oncogenes is usually achieved by using retroviral or lentiviral vectors. However, the use of 
integrating viral vectors represent a major obstacle to the therapeutic translation of iPS cells 
as this technology can produce insertional mutagenic lesions that are potentially 
tumorigenic. Other methods to reprogram cells are now being intensively tested, such as the 
use of secreted recombinant reprogramming factors present in the culture media. These iPS 
cells are morphologically and phenotypically similar to embryonic stem (ES) cells and thus 
offer exciting possibilities in stem cell research and regenerative medicine. This method has 
been successfully applied to ALS patients and allowed to study iPS-derived motor neurons 
in vitro (Dimos, et al., 2008; Mitne-Neto, et al., 2011). Since this technology is still recent, it is 
not clear whether motor neurons and glial cells derived from ALS patients-iPS cells will 
efficiently recapitulate the disease in vitro. However, these cells seem to behave like ESCs 
and even if they only partly mimic the ALS phenotype in culture, they certainly will be 
extremely interesting to use, especially for a better understanding of sporadic ALS. 
3.6 Three-dimensional in vitro models 
Now that iPS or NPCs ALS patient-derived motor neurons and glial cells will be available to 
develop better ALS in vitro models, their design could also be improved. The culture of 
neural cells in two dimensions on plastic does not mimic properly the in vivo situation. 
Building three-dimensional environment around ALS patient-derived neural cells could be a 
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major improvement in the development of in vitro models of the disease. The culture of 
NPCs in methylcellulose scaffold enriched with laminin has been shown to reduce apoptosis 
and enhance survival, differentiation into neurons, astrocytes or oligodendrocytes and 
neurite extension (Cullen, et al., 2007; Stabenfeldt, et al., 2010). Motor neurons axonal 
migration can also be analyzed when these cells are cultured on the top of a three-
dimensional reconstructed connective tissue made of a collagen sponge populated with 
fibroblasts. The addition of neurotrophic factors underneath the construct promotes neurite 
growth from the top to the bottom of the tissue. The main advantage of this model is to 
enable myelin sheath formation by Schwann cells around axons in the connective tissue and 
the possibility to add various glial cells (astrocytes, microglia) in the motor neuron layer (Fig 
5) (Gingras, et al., 2008). In addition, it is possible to easily combine cells from different 
origin, like WT motor neurons with ALS glial cells, and vice-versa in order to further 
explore the non-cell autonomous effect observed in SOD1-linked ALS pathology. Such 
combinations could also be very informative in the study of sporadic ALS. Alternatively, a 3 
dimensional reconstructed muscle model has been developed to study in vitro the effect of 
muscle stretching on mRNA expression of muscle cells. This model was prepared using 
primary muscle cultures from human control subjects and ALS patients. The cells were 
embedded in a collagen gel tethered to a Culture Force Monitor to analyze gel contraction 
(Cheema, et al., 2003; Evans, et al., 2010).  
Finally, the combination of ALS patient NPC-derived neural cells in tissue-engineered 
reconstructed spinal cord models is a promising strategy to develop the next generation of 
in vitro models of ALS. 
 
 
Fig. 5. Three-dimensional model of motor neuron axonal migration and myelin sheath 
formation.  
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In A, after the culture of fibroblasts and Schwann cells for 21 days in a collagen sponge (blue 
area), mouse motor neurons were seeded on top of the sponge (purple area) and cultured 
for an additional 14 days and observed by histology staining with Masson’s trichrom. In B, 
axonal migration (stained in green with an antibody against Neurofilament-M) originating 
from the top layer was shown migrating through the connective tissue. In C, a transmission 
electron microscopic picture showed that some neurites were wrapped with thick myelin 
sheaths, observed at higher magnification in D.  Bar in A, 60µm; bar in B, 100µm; bar in C, 
2µm; bar in F, 0,2µm (Modified from Gingras, et al., 2008). 
4. Conclusion 
A very large body of knowledge has been built over the years with the development of 
various in vivo models to better understand ALS. Particularly, the generation of a large 
number of different transgenic mice has been extremely useful to study familial ALS, but 
has met with limited success so far to study SALS or to identify drugs alleviating the disease 
symptoms. This could be explained by the existence of redundant compensatory 
mechanisms present in higher vertebrates. The use of invertebrates together with higher 
animal models will hopefully allow the identification of novel pathogenic pathways and 
novel therapeutic avenues in order to cure this devastating disease. 
In parallel, the development of in vitro models will give valuable information about the 
intracellular modulations induced by the disease. In addition, the promise of building 
sophisticated in vitro models using patient’s cells will also be crucial to better understand the 
disease. However, the results obtained from in vitro models may not always be relevant 
because they are oversimplified compared to the in vivo situation. Therefore, the best 
strategy to reduce the limitations inherent to all these different models, and to benefit from 
their specific advantages is to combine both in vivo and in vitro models in order to better 
model the disease. Future work, focusing on different neuronal in vitro system and animal 
models, will certainly increases our knowledge in the biology of ALS and hopefully leads to 
more translational researches in order to find a cure or to slow down the course of this yet 
untreatable disease. 
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